Quarterly ResultAug 3, 2026, 06:34 AM
Indivior Q2 Revenue $343M, Adj. EBITDA +111%; Raises FY26 Guidance
AI Summary
Indivior Pharmaceuticals reported strong financial results for Q2 2026, with total net revenue increasing 14% year-over-year to $343 million and record Adjusted EBITDA of $186 million, up 111%. The company also raised its full-year 2026 financial guidance, driven by exceptional SUBLOCADE performance, which achieved record quarterly net revenue of $253 million. Indivior repurchased $175 million in shares during the quarter and anticipates closing its proposed merger with Supernus in the fourth quarter.
Key Highlights
- Raised full-year 2026 total net revenue guidance to $1.295B-$1.365B.
- Raised full-year 2026 Adjusted EBITDA guidance to $700M-$740M.
- Q2 2026 total net revenue was $343 million, up 14% year-over-year.
- Q2 2026 SUBLOCADE net revenue was $253 million, up 21% year-over-year.
- Q2 2026 Adjusted EBITDA was $186 million, up 111% year-over-year.
- Q2 2026 GAAP net income was $122 million ($0.98 diluted EPS).
- Repurchased 4.7 million shares for $175 million in Q2 2026.
- Proposed merger with Supernus expected to close in Q4 2026.
Price Impact
More from INDV